Yang Jae Yoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1896554/publications.pdf

Version: 2024-02-01

1040056 1281871 11 435 9 11 citations h-index g-index papers 11 11 11 905 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. Korean Journal of Internal Medicine, 2020, 35, 1346-1353.	1.7	3
2	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut and Liver, 2018, 12, 94-101.	2.9	14
3	Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. Scientific Reports, 2017, 7, 3710.	3.3	170
4	Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. Journal of Medical Virology, 2017, 89, 849-856.	5.0	9
5	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Journal of Korean Medical Science, 2017, 32, 212.	2.5	34
6	Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review. Clinical and Molecular Hepatology, 2017, 23, 340-346.	8.9	19
7	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 467-474.	2.8	47
8	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	2.5	33
9	Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 12787.	3.3	51
10	Caroli's disease misdiagnosed as intraductal papillary neoplasm of the bile duct. Clinical and Molecular Hepatology, 2015, 21, 175.	8.9	15
11	Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. Gut and Liver, 2014, 8, 177-185.	2.9	40